Guided Therapeutics' shares soaring ahead of pending FDA decision |
![]() |
![]() |
By M.E.Garza | |
Sunday, 11 December 2011 04:46 | |
![]()
For those of you not familiar with the company, Guided Therapeutics developed Biophotonics technology that is used in medicine to study tissue and blood at the macro (large-scale) and micro (very small scale) organism level to detect, diagnose and treat diseases in a way that are non-invasive to the body. Its LuViva™ Advanced Cervical Scan uses light to detect chemical and structural changes in cervical tissue. The technology being developed for the cancer product is called hyperspectral imaging spectroscopy or HIS. HIS acquires the individual spectrum of each cell component while it is in the body. The device then identifies physiological markers of cancer based on their spectral signatures. LuViva is currently under U.S. Food and Drug Administration (FDA) premarket application review and our BioMedReports FDA Calendar shows that the FDA has informed Guided Therapeutics that the agency expects to rule on the application by January 20, 2012, but a decision could come much sooner according to our sources. Shares traded nearly seven times the daily average volume and closed at the three-year resistance levels. If the stock breaks past those resistance levels, it could see another effusive run, particularly if the firm recives news from U.S. regulators early. Strong positive news would likely impact the firm's moderately priced ($70M) market cap, especially given the increasingly tigher float. Only 13K of the total outstanding shares (roughly 49 million) are currently short the stock.
Additionally, the clinical trials indicated that women aged 16-20 were just as likely to have cervical disease as women 21 and older and current methods of early detection, such as HPV testing, are not recommended for this age group. LuViva detected cervical disease equally well in both adolescent and adult women. In August the firm announced that it began human testing of its light-based detection technology for Barrett’s Esophagus, a precursor for esophageal cancer. That technology is being jointly developed with Konica Minolta Opto of Japan. "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |